New Delhi, India — January 27, 2026
India has marked a significant milestone in medical science and cancer treatment, as a leading domestic pharmaceutical company has successfully completed Phase-3 clinical trials of a new immunotherapy-based drug for lung cancer.
According to a report released on January 27, 2026, the drug demonstrated approximately 40 percent higher effectiveness than conventional chemotherapy in treating advanced stages of lung cancer, with improved patient outcomes and fewer side effects.
Immunotherapy: A Shift From Traditional Chemotherapy
Unlike traditional chemotherapy—which targets both cancerous and healthy cells and often causes severe side effects—the new drug is based on immunotherapy.
Immunotherapy works by training the body’s own immune system to recognize and destroy cancer cells more effectively. This targeted approach helps preserve healthy tissue and improves overall treatment tolerance.
Strong Results in Lung Cancer Trials
Data from Phase-3 clinical trials indicate that:
The drug is 40 percent more effective than chemotherapy in advanced lung cancer cases
Patients showed a significant improvement in survival rates
Side effects were substantially fewer and more manageable compared to standard chemotherapy
Experts note that these outcomes represent a meaningful advancement, particularly for patients with late-stage lung cancer, where treatment options are often limited.
Affordable ‘Make in India’ Cancer Treatment
Because the drug has been developed by an Indian pharmaceutical company—similar to major domestic players operating in the immunotherapy space—its cost is expected to be 70–80 percent lower than imported immunotherapy drugs.
This could make world-class cancer treatment far more accessible for patients in India and other developing nations, where high treatment costs remain a major barrier to care.
Regulatory Path Ahead
Following the successful completion of Phase-3 trials, the drug has now been submitted to the Drugs Controller General of India (DCGI) for final regulatory approval.
If approved, the medication is expected to become available in Indian hospitals and pharmacies by mid-2026. Official updates related to approval and launch are expected to be published on the CDSCO (Government of India) portal.
Expert Opinion
Oncology specialists believe this development could be a turning point not only for India but for other developing countries, where access to advanced cancer therapies remains limited.
Experts emphasize that while immunotherapy is not suitable for all patients, the availability of a cost-effective, domestically developed option could significantly expand treatment access and improve outcomes.
For additional guidance and cancer-related support, patients are advised to consult certified oncologists or resources such as the National Cancer Institute (India).
